sees fy sales $4.9 billion to $5.3 billion.
sees fy adjusted earnings per share $2.00 to $2,20 excluding items.
sees q1 adjusted earnings per share $0.43 to $0.,50 excluding items.
q4 adjusted earnings per share $0.50.
q3 gaap earnings per share $0.49.
sees surgical structural heart sales in range of $800 million to $900 million for fiscal 2022.
sees q3 sales $3.2 billion to $33.6 billion.
sees fy sales $4.9 billion to $5.3 billion.
sees full-year 2020 global sales of $762 million, down 10% on an underlying basis over prior year.
q4 sales $204 million versus refinitiv ibes estimate of $207.7 million.
qtrly adjusted earnings per share $1.86.
qtrly global tavr sales of 2.9 billion increased 4% on an underlying basis over prior year.
sees fy 2021 average diluted shares outstanding to be between 630 and 635 million.
q4 sales $1.2 billion versus refinitiv ibes estimate of $1 billion.
q4 sales $13 million versus refinitiv ibes estimate of $12.7 million.
sees fy 2020 global sales of $725 million to $715 million.
